Novel Small-Molecule Atypical Chemokine Receptor 3 Agonists: Design, Synthesis, and Pharmacological Evaluation for Antiplatelet Therapy
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.4c01371 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Alp Bayrak und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmacy, Pharmaceutical/Medicinal Chemistry, Eberhard Karls University Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany. Hauptthemen laut MEDLINE: Platelet Aggregation Inhibitors, Drug Design, Platelet Aggregation, Receptors, CXCR. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: Bundesministerium für Bildung und Forschung, Fonds National de la Recherche Luxembourg, Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
ACKR3, an atypical chemokine receptor, has been associated with prothrombotic events and the development of cardiovascular events. We designed, synthesized, and evaluated a series of novel small molecule ACKR3 agonists. Extensive structure-activity relationship studies resulted in several promising agonists with potencies ranging from the low micromolar to nanomolar range, for example, 23 (EC50 = 111 nM, Emax = 95%) and 27 (EC50 = 69 nM, Emax = 82%) in the β-arrestin-recruitment assay. These compounds are selective for ACKR3 versus ACKR2, CXCR3, and CXCR4. Several agonists were subjected to investigations of their P-selectin expression reduction in the flow cytometry experiments. In particular, compounds 23 and 27 showed the highest potency for platelet aggregation inhibition, up to 80% and 97%, respectively. The most promising compounds, especially 27, exhibited good solubility, metabolic stability, and no cytotoxicity, suggesting a potential tool compound for the treatment of platelet-mediated thrombosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Pharmacy, Pharmaceutical/Medicinal Chemistry, Eberhard Karls University Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany.
- Department of Infection and Immunity, Immuno-Pharmacology and Interactomics, Luxembourg Institute of Health (LIH), L-4354 Esch-sur-Alzette, Luxembourg.
- Department of Internal Medicine III, Cardiology and Angiology, University Hospital Tübingen, Otfried-Müller-Strasse 10, 72076 Tübingen, Germany.
- Tübingen Center for Academic Drug Discovery (TüCAD2), Auf der Morgenstelle 8, 72076 Tübingen, Germany.
- iFIT Cluster of Excellence (EXC 2180) "Image-guided and Functionally Instructed Tumor Therapies", Eberhard Karls University Tübingen, 72076 Tübingen, Germany.
ORCID-Profile: Alp Bayrak, Martyna Szpakowska, Valerie Dicenta-Baunach, Andy Chevigné, Stefan A Laufer, Thanigaimalai Pillaiyar
Förderung
- Bundesministerium für Bildung und Forschung
- Fonds National de la Recherche Luxembourg
- Deutsche Forschungsgemeinschaft
- Fonds De La Recherche Scientifique - FNRS
- University of Tübingen
Zitieren
APA
Bayrak, A., Szpakowska, M., Dicenta-Baunach, V., Counson, M., Rasch, A., Rohlfing, A. K., Chevigné, A., Gawaz, M., Laufer, S. A., & Pillaiyar, T. (2024). Novel Small-Molecule Atypical Chemokine Receptor 3 Agonists: Design, Synthesis, and Pharmacological Evaluation for Antiplatelet Therapy. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c01371
Vancouver
Bayrak A, Szpakowska M, Dicenta-Baunach V, Counson M, Rasch A, Rohlfing AK, et al. Novel Small-Molecule Atypical Chemokine Receptor 3 Agonists: Design, Synthesis, and Pharmacological Evaluation for Antiplatelet Therapy. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c01371
BibTeX
@article{Bayrak2024,
author = {Bayrak, Alp and Szpakowska, Martyna and Dicenta-Baunach, Valerie and Counson, Manuel and Rasch, Alexander and Rohlfing, Anne-Katrin and Chevigné, Andy and Gawaz, Meinrad and Laufer, Stefan A and Pillaiyar, Thanigaimalai},
title = {Novel Small-Molecule Atypical Chemokine Receptor 3 Agonists: Design, Synthesis, and Pharmacological Evaluation for Antiplatelet Therapy},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.4c01371}
}
EUVIMED